The study will evaluate several dose strengths of VIBEX MTX which is being developed for the treatment of rheumatoid arthritis.
VIBEX MTX is Antares’ proprietary – wholly owned methotrexate injection system engineered for rapid self-administration by patients – and protected by several issued and pending patents.
Antares has already conducted in-vivo, pre-clinical studies which demonstrated reproducible pharmacokinetics and good injection site tolerance when methotrexate was delivered using the VIBEX technology.
Antares president and CEO Paul Wotton said that a significant number of patients are unable to tolerate methotrexate when given orally, but when it is administered in combination with injectable biological products, VIBEX MTX may represent a significant revenue opportunity for Antares; potentially as early as in 2013.